Home › Funds › Affinity Asset Advisors, LLC › JBIO

Affinity Asset Advisors, LLC position in JBIO

JADE BIOSCIENCES INC · Health Care

Affinity Asset Advisors, LLC reported holding 760,350 shares of JBIO (JADE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$10.7M, representing 0.50% of its reported portfolio and ranking #46 among its reported holdings. Affinity Asset Advisors, LLC has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

Latest position (Q3 2026)760.35K sh
Reported value held$10.68M
Portfolio Weight0.50%
First reportedQ2 2025
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Affinity Asset Advisors, LLC's JBIO position evolved

Affinity Asset Advisors, LLC first disclosed a stake in JBIO in Q2 2025 at 65,317 shares (US$653K). The position peaked in Q2 2026 at 840,350 shares, worth US$18.7M. Across 6 filings, Affinity Asset Advisors, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 760,350 shares valued at US$10.7M — a reduction of -80,000 shares quarter over quarter.. Notable position changes include a 995% increase in Q4 2025 (shares fell 9% over the following quarter), a 31% increase in Q2 2026 (shares fell 37% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 65.32K $652.52K New
Q3 2025 65.32K $563.69K Hold
Q4 2025 714.96K $11.03M Add
Q1 2026 639.96K $8.99M Reduce
Q2 2026 840.35K $18.67M Add
Q3 2026 760.35K $10.68M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JBIO and 13F data

JBIO (JADE BIOSCIENCES INC) is a Health Care company. 94 other funds we track also report a position in JBIO — the largest reported positions include Fairmount Funds Management LLC (US$101.2M), RA CAPITAL MANAGEMENT, L.P. (US$81.6M), Venrock Adviser, LLC (US$71.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JBIO

All JBIO fund holders →

FAQ

How long has Affinity Asset Advisors, LLC held JBIO?

Affinity Asset Advisors, LLC has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

What is Affinity Asset Advisors, LLC's current position in JBIO?

As of Q3 2026, Affinity Asset Advisors, LLC holds 760.35K shares of JBIO (JADE BIOSCIENCES INC), valued at $10.68M, representing 0.50% of its reported portfolio and ranking #46.

Has Affinity Asset Advisors, LLC been buying or selling JBIO?

In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC reduced its position in JBIO. The position peaked in Q2 2026 at 840.35K shares.

Which other funds hold JBIO?

Other major institutional holders of JBIO include Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Venrock Adviser, LLC, among 94 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.